Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?

被引：1
|
作者：
Spieler, Benjamin Oren
Lopes, Gilberto
Dal Pra, Alan
Diwanji, Tejan
Yechieli, Raphael
Freedman, Laura M.
Mihaylov, Ivaylo
机构：
[1] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[2] Univ Miami Hlth Syst, Miami, FL USA
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Univ Miami, Parkland, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9579
引用
收藏
页数：2
相关论文
共 50 条
  • [31] 5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy
    Bjornhart, Birgitte
    Mouritzen, Mette Thune
    Kristiansen, Charlotte
    Schytte, Tine
    Wedervang, Kim
    Pohl, Mette
    Hansen, Karin Holmskov
    ACTA ONCOLOGICA, 2023, 62 (08) : 861 - 870
  • [32] Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor therapy in advanced-stage non-small cell lung cancer patients.
    Multani, Maneet
    Tarhoni, Imad
    Fughhi, Ibdihaj
    Basu, Sanjib
    Batus, Marta
    Bonomi, Philip D.
    Fidler, Mary J.
    Borgia, Jeffrey Allen
    Shah, Palmi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
    Min Luo
    Yuhui Xia
    Fang Wang
    Hong Zhang
    Danting Su
    Chaoyue Su
    Chuan Yang
    Shaocong Wu
    Sainan An
    Suxia Lin
    Liwu Fu
    Acta Pharmaceutica Sinica B, 2021, 11 (10) : 3120 - 3133
  • [34] PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
    Luo, Min
    Xia, Yuhui
    Wang, Fang
    Zhang, Hong
    Su, Danting
    Su, Chaoyue
    Yang, Chuan
    Wu, Shaocong
    An, Sainan
    Lin, Suxia
    Fu, Liwu
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (10) : 3120 - 3133
  • [35] Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
    Chao, Yencheng
    Zhou, Jiebai
    Hsu, Shujung
    Ding, Ning
    Li, Jiamin
    Zhang, Yong
    Xu, Xiaobo
    Tang, Xinjun
    Wei, Tianchang
    Zhu, Zhengfei
    Chu, Qian
    Neal, Joel W.
    Wu, Julie Tsu-Yu
    Song, Yuanlin
    Hu, Jie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (02) : 295 - +
  • [36] Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer A case report
    Zhang, Lin
    Mai, Wuqian
    Hao, Bo
    Jiang, Wenyang
    Geng, Qing
    MEDICINE, 2020, 99 (21) : E19790
  • [37] Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Li Pang
    Mei Xie
    Xidong Ma
    Aiben Huang
    Jialin Song
    Jie Yao
    Hui Deng
    Duchao Zhang
    Xuelei Zang
    Fangping Ren
    Jie Gao
    Chongchong Wu
    Yuanyong Wang
    Xin Zhang
    Xinyu Bao
    Lei Pan
    Xinying Xue
    BMC Cancer, 23
  • [38] The prognostic impact of severe grade immune checkpoint inhibitor related pneumonitis in non-small cell lung cancer patients
    Sun, Ni
    Li, Ru
    Deng, Haiyi
    Li, Qingyang
    Deng, Jiaxi
    Zhu, Yue
    Mo, Wenwei
    Guan, Wenhui
    Hu, Minjuan
    Liu, Ming
    Xie, Xiaohong
    Lin, Xinqing
    Zhou, Chengzhi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [39] Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
    Shu, Yang
    Xu, Wei
    Su, Rui
    Ran, Pancen
    Liu, Lei
    Zhang, Zhizhao
    Zhao, Jing
    Chao, Zhen
    Fu, Guobin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [40] Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer
    Nishiyama, Osamu
    Shimizu, Shigeki
    Haratani, Koji
    Isomoto, Kosuke
    Tanizaki, Junko
    Hayashi, Hidetoshi
    Yamazaki, Ryo
    Oomori, Takashi
    Nishikawa, Yusaku
    Sano, Akiko
    Nakagawa, Kazuhiko
    Tohda, Yuji
    BMC PULMONARY MEDICINE, 2021, 21 (01)
12345